<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02197299</url>
  </required_header>
  <id_info>
    <org_study_id>14/EM/0136</org_study_id>
    <secondary_id>13/0004659</secondary_id>
    <nct_id>NCT02197299</nct_id>
  </id_info>
  <brief_title>Improving Glycaemic Control With L-carnitine</brief_title>
  <official_title>Increasing Skeletal Muscle Carnitine Content to Improve Glycaemic Control in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A characteristic of Type 2 diabetes is a high blood glucose level, which is partly caused by
      the inability of insulin to stimulate glucose uptake into our muscles (insulin resistance).
      Insulin resistance can be caused by the accumulation of fat within muscle of overweight
      individuals. The aim of the present research is to test whether a novel nutritional
      intervention containing L-carnitine can increase the amount of carnitine within muscle of
      individuals recently diagnosed with Type 2 diabetes. Carnitine is essential for 'burning fat'
      within our muscles and it is hoped that increasing the amount of carnitine within muscle can
      increase fat burning, lower muscle fat, reverse insulin resistance and ultimately lower blood
      glucose levels and wellbeing. We also aim to investigate the cellular mechanisms underlying
      any observed effects in a hope to identify further targets to lower muscle fat.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal muscle total carnitine content</measure>
    <time_frame>up to 24 weeks of L-carnitine supplementation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of 4.5 g L-carnitine L-tartrate (containing 3 g L-carnitine; Carnipure, Lonza Ltd., Switzerland) once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of placebo sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-carnitine</intervention_name>
    <arm_group_label>Carnitine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) 27-37 kg/m2

          -  Male

          -  Age 18-60 years old

          -  Type 2 diabetes mellitus reasonably well controlled (HbA1c less than or equal to 58
             mmol/mol) on diet therapy or metformin alone

          -  Not taking anti-diabetes medication other than metformin

          -  Understand verbal and/or written explanation of the study requirements

        Exclusion Criteria:

          -  Malignancy (excluding localised basal and squamous cell skin cancer)

          -  Metabolic diseases (stable treated hypothyroidism allowed)

          -  Active cardiovascular disease (current angina, myocardial infarct, or coronary artery
             surgery/angioplasty within 12 months)

          -  Primary muscle disorders

          -  Cerebrovascular disease

          -  Neurological disease e.g. epilepsy, Parkinsons disease

          -  Active respiratory disease

          -  Active gastrointestinal or liver disease

          -  Renal impairment (eGFR &lt;60 ml/min)

          -  Clotting dysfunction

          -  Anti-diabetes medication other than metformin

          -  Other medications that may affect glucose tolerance (e.g. corticosteroids), muscle
             metabolism, or safety (e.g. anticoagulants)

          -  Any other conditions in addition to the above that the investigators consider may
             affect study measurements or safety
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis B Stephens, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Nottingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francis B Stephens, PhD</last_name>
    <phone>00441158230398</phone>
    <email>francis.stephens@nottingham.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>David Greenfield Human Physiology Unit, School of Life Sciences, The University of Nottingham</name>
      <address>
        <city>Nottingham</city>
        <zip>NG72UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Brown</last_name>
      <email>sara.brown@nottingham.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Francis B Stephens, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2014</study_first_submitted>
  <study_first_submitted_qc>July 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2014</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

